Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Court to FDA: Approve Watson’s Actos ANDA, Award Shared Exclusivity

Washington Drug Letter

Oct. 29, 2012 | Vol. 44 No. 43

Court to FDA: Approve Watson’s Actos ANDA, Award Shared Exclusivity

A district court has ordered the FDA to immediately approve Watson’s ANDA for a generic of Takeda’s billion-dollar diabetes treatment Actos.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Merck Loses Another Round In Fight To Fend Off Generic Nasonex FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAs Two Ex-FDA Commissioners Say Generic Makers Don’t Get Free Pass on State Suits FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone Generics

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.